热门资讯> 正文
Nektar Therapeutics继续飙升，股价再上涨25%
2025-06-26 02:14
- 内克塔治疗(NKTR) 0
- 纳比特(NA) 0
- 盛大科技(SDA) 0
- Nektar Therapeutics (NASDAQ:NKTR), which closed Tuesday up ~156% after its lead asset, rezpegaldesleukin, met its main goal in a mid-stage trial for atopic dermatitis, also known as eczema, is up another 25% in Wednesday afternoon trading.
- "We believe that the REZOLVE-AD study results clearly demonstrate that Nektar has established a new biology and harnessed the promise of (regulatory T cell proliferators) as an important potential therapeutic modality to treat inflammatory skin disorders and other autoimmune conditions," Nektar CEO Howard Robin said in a statement.
- Results showed that between 34% and 46% of patients had at least a 75% improvement in eczema symptoms.
- The company plans to release data from the long-term maintenance section of REZOLVE-AD in Q1 2026.
More on Nektar Therapeutics
- Nektar Therapeutics: 2 Data Readouts For REZPEG 2025 Could Establish Further POC
- Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Transcript
- Nektar surges as lead asset succeeds in mid-stage trial for eczema
- Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit
- Seeking Alpha’s Quant Rating on Nektar Therapeutics
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
